HK:6855 Stock Latest News

Ascentage Pharma to Showcase Six Cancer Drug Studies at 2026 ASCO Meeting

PremiumCompany Announcements

7d ago

Ascentage Pharma Grants New RSUs to Top Executives Under 2022 Incentive Scheme

PremiumCompany Announcements

8d ago

Ascentage Pharma Showcases Promising Combination Oncology Data at AACR 2026

PremiumCompany Announcements

9d ago

Ascentage Pharma management to meet with Piper Sandler

PremiumThe Fly

20d ago

PremiumThe FlyAscentage Pharma management to meet with BTIG

26d ago

Ascentage Pharma Relocates Hong Kong Principal Office and Highlights Global Governance Standards

Company Announcements

Ascentage Pharma Relocates Hong Kong Principal Office and Highlights Global Governance Standards

27d ago

Ascentage Pharma Advances Pivotal APG-2575 Trial in Difficult-to-Treat CLL/SLL

Company Announcements

Ascentage Pharma Advances Pivotal APG-2575 Trial in Difficult-to-Treat CLL/SLL

1M ago

Ascentage Pharma Ramps Up Sales, Dual Listing and Late-Stage Oncology Pipeline in 2025

PremiumCompany Announcements

1M ago

Ascentage Pharma Showcases Four Preclinical Cancer Programs at 2026 AACR Meeting

PremiumCompany Announcements

1M ago

Ascentage Pharma Sets March Board Meeting to Approve 2025 Results and Consider Final Dividend

PremiumCompany Announcements

2M ago

Ascentage Pharma initiated with a Buy at BTIG

PremiumThe Fly

2M ago

PremiumRatingsAscentage Pharma: Undervalued Long-Term Oncology Leader Backed by Late-Stage Assets Olverembatinib and Lisaftoclax

2M ago

Ascentage Pharma Launches New Phase I Blood Cancer Trial That Could Shape Its Pipeline Outlook

Company Announcements

Ascentage Pharma Launches New Phase I Blood Cancer Trial That Could Shape Its Pipeline Outlook

2M ago

Ascentage Pharma announces IND clearance by the China CDE for APG-3288

The Fly

Ascentage Pharma announces IND clearance by the China CDE for APG-3288

3M ago

Ascentage Pharma initiated with a Buy at Rodman & Renshaw

PremiumThe Fly

3M ago

Ascentage Pharma’s APG-3288 receives IND clearance from FDA

PremiumThe Fly

4M ago

Ascentage Pharma Enhances Board Structure, Sets Shareholder Vote on Equity Grant

PremiumCompany Announcements

4M ago

Ascentage Pharma Sets Out Board Line-Up and Key Committee Roles

PremiumCompany Announcements

4M ago

Ascentage Pharma Advances Olverembatinib With New Liver Function Study, Offering Gradual Upside for Investors

PremiumCompany AnnouncementsAscentage Pharma Advances Olverembatinib With New Liver Function Study, Offering Gradual Upside for Investors

4M ago

Ascentage Pharma initiated with a Buy at Lucid Capital

The Fly

Ascentage Pharma initiated with a Buy at Lucid Capital

4M ago

Ascentage Pharma presents data from Phase Ib/II study of Lisaftoclax

The Fly

Ascentage Pharma presents data from Phase Ib/II study of Lisaftoclax

5M ago